Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Patterns of use of sildenafil among commercially insured adults in the United States: 1998–2002

International Journal of Impotence Research volume 16, pages 313–318 (2004)Cite this article

Abstract

Sildenafil is increasingly being marketed to younger healthcare consumers. The purpose of this study was to profile sildenafil use in commercially insured, adult beneficiaries. Annual ambulatory prescription claims data from 1998 to 2002, for a nationwide, random sample of over 5 million life-years of commercially insured adults (aged ≥18 y), were examined retrospectively. The overall prevalence of sildenafil use increased from 0.8% (1998) to 1.4% (2002), an 84% increase. While the growth in use slowed in older males, use became more pronounced in younger males and females and decreased in older females. The fastest growing segment of users was found to be males aged 18–45 y. The proportion of users who had two or more claims for a medication that is suspected of inducing erectile dysfunction (ED) and/or a marker for a suspected ED-inducing disease decreased over the study period. Our findings suggest that use may increase among younger male and female patients and those without an underlying etiologic reason for use.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, 1994, pp 493–522.

  2. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    Article  CAS  Google Scholar 

  3. Ragucci KR, Culhane NS . Treatment of female sexual dysfunction. Ann Pharmacother 2003; 37: 546–555.

    Article  CAS  Google Scholar 

  4. Chew KK et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41–45.

    Article  CAS  Google Scholar 

  5. Slag M et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736–1740.

    Article  CAS  Google Scholar 

  6. Benet AE, Melman A . The epidemiology of erectile dysfunction. Urol Clin N Am 1995; 22: 699–709.

    CAS  Google Scholar 

  7. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

  8. Gingell C et al. Guidance on the management of erectile dysfunction in primary care. Prescriber 1999; 5(Suppl): 1–19.

    Google Scholar 

  9. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  10. Kaiser FE et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36: 511–519.

    Article  CAS  Google Scholar 

  11. Mulligan T, Katz PG . Why aged men become impotent. Arch Intern Med 1989; 149: 1365–1366.

    Article  CAS  Google Scholar 

  12. Hanash KA . Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997; 157: 2135–2138.

    Article  CAS  Google Scholar 

  13. Jarow JP et al. Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609–1612.

    Article  CAS  Google Scholar 

  14. Lamberg L . New drug for erectile dysfunction boon for many, ‘viagravation’ for some. JAMA 1998; 280: 867–869.

    Article  CAS  Google Scholar 

  15. Viagra Package Insert. Available at: http://www.viagramd.com/pi/proPackInsert.asp. Accessed July 21, 2003.

  16. Kaplan SA et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481–486.

    Article  CAS  Google Scholar 

  17. Caruso S, Intelisano G, Lupo L, Agnello C . Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled trial. Br J Obstet Gynaecol 2001; 108: 623–628.

    CAS  Google Scholar 

  18. Rosen RC . Sildenafil: medical advance or media event. Lancet 1998; 351: 1599–1600.

    Article  CAS  Google Scholar 

  19. Braun M, Klotz T, Mathers MJ . ‘Viagra Effect’ —influence of mass media on patient behavior. Urol Int 2001; 66: 145–148.

    Article  CAS  Google Scholar 

  20. Leland J . Ideas and Trends: Big Pharma Ogles Yasgur's Farm, The New York Times, 2001, July 29, Section 4 p 3.

  21. Klein R, Sturm H . Viagra: a success story for rationing? Health Aff (Millwood) 2002; 21: 177–187.

    Article  Google Scholar 

  22. Keith A . The economics of Viagra. Health Aff (Millwood) 2000; 19: 147–157.

    Article  CAS  Google Scholar 

  23. Titlow K, Randel L, Clancy CM, Emanuel EJ . Drug coverage decisions: the role of dollars and values. Health Aff (Millwood) 2000; 19: 240–247.

    Article  CAS  Google Scholar 

  24. Mitrany D . Lifestyle drugs: determining their value and who should pay. Pharmacoeconomics 2001; 19: 441–448.

    Article  CAS  Google Scholar 

  25. Rosenthal MB et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346: 498–505.

    Article  Google Scholar 

  26. Loyd L . Pharmaceutical Firms take Fight for Impotence Drug Users to the Mat, Philadelphia Inquirer, 2003, July 6, p. E01.

  27. Lim PH, Moorthy P, Benton KG . The clinical safety of Viagra. Ann NY Acad Sci 2002; 962: 378–388.

    Article  CAS  Google Scholar 

  28. Kloner RA . Viagra: what every physician should know. Ear Nose Throat J 1998; 77: 783–786.

    CAS  PubMed  Google Scholar 

  29. Kloner RA, Jarow JP . Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576–582, A7.

    Article  CAS  Google Scholar 

  30. Harrold LR et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med 2000; 160: 3401–3405.

    Article  CAS  Google Scholar 

  31. First DataBank (Medi-Span). Generic Product Identifier Number. First DataBank (Medi-Span): Indianapolis, IN, 2001.

  32. McLeod AL, McKenna CJ, Northbridge DB . Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin Cardiol 2002; 25: 133–134.

    Article  CAS  Google Scholar 

  33. Colfax GN et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001; 28: 373–379.

    Article  CAS  Google Scholar 

  34. Schwartz RK, Soumerai SB, Avorn J . Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989; 28: 577–582.

    Article  CAS  Google Scholar 

  35. Ashworth M, Clement S, Wright M . Demand, appropriateness and prescribing of ‘lifestyle drugs’: a consultation survey in general practice. Fam Pract 2002; 19: 236–241.

    Article  Google Scholar 

  36. Wilson ECF et al. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics 2002; 20: 879–889.

    Article  Google Scholar 

  37. Maguire P . How direct to consumer advertising is putting the squeeze on physicians. Available at: http://www.acponline.org/shell-cgi/printhappy.pl/journals/news/mar99/squeeze.htm. Accessed July 22, 2003.

  38. Lewis RW . Epidemiology of erectile dysfunction. Urol Clin N Am 2001; 28: 209–216.

    Article  CAS  Google Scholar 

  39. McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12(Suppl 4): S6–S11.

    Article  Google Scholar 

Download references

Acknowledgements

We express our appreciation to Dr Jagat Sheth for his assistance. This study was funded by Express Scripts, Inc.

Author information

Authors and Affiliations

  1. Express Scripts, Inc., 13900 Riverport Dr. STL12N, Maryland Heights, Missouri, USA

    T Delate, V A Simmons & B R Motheral

Authors
  1. T Delate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V A Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B R Motheral
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Delate.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delate, T., Simmons, V. & Motheral, B. Patterns of use of sildenafil among commercially insured adults in the United States: 1998–2002. Int J Impot Res 16, 313–318 (2004). https://doi.org/10.1038/sj.ijir.3901191

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901191

Keywords

This article is cited by

Search

Advanced search

Quick links